info@iozk.de
  • Home page
  • The IOZK
    • Philosophy
    • Team
    • Treatment center
    • Laboratories
    • Career
    • Arrival and overnight stay
  • The IOZK immunotherapy
    • IOZK immunotherapy
    • IO-VAC vaccine
    • Treatment procedure
    • Therapy costs
    • FAQ
  • Specialist knowledge
    • IOZK Publications
    • International publications
    • Worth knowing
    • IOZK Podcasts
  • Latest news
  • Contact us
  • menu Menu

Dr. Wilfried Stücker

Management and leadership of the IOZK working group

The IOZK's vision: to put immuno-oncological research findings into practice in a timely manner

Dr. Wilfried Stücker is Managing Director of the IOZK and the IOZK Foundation. In 1985, he initiated today's Immuno-Oncology Center Cologne. In collaboration with various doctors and scientists, he developed the IOZK immunotherapy and set up the treatment center with the laboratories.
The IOZK Foundation was established in 2019 to optimize immunotherapies against cancer.

"Prolonging the lives of cancer patients and offering them gentle treatment is what we at the IOZK are committed to with our expertise."

Dr. Wilfried Stücker

Collection: Scientific contributions and international publications by Dr. Wilfried Stücker

The Complexity of Malignant Glioma Treatment

2025-03-04
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2025-03-04 / Cancers (Basel) 2025 Mar;17(5) https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2025-03-04 / Cancers (Basel) 2025 Mar;17(5)2025-03-04 00:00:002025-03-17 07:36:12The Complexity of Malignant Glioma Treatment

Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution

2024-03-28
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2024-03-28 / Biomedicines 2024 Mar;12(4) https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2024-03-28 / Biomedicines 2024 Mar;12(4)2024-03-28 00:00:002024-04-30 08:35:31Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution

Methods behind oncolytic virus-based DC vaccines in cancer: Toward a multiphase combined treatment strategy for Glioblastoma (GBM) patients

2023-10-19
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2023-10-19 / Methods Cell Biol 2024;183:51-113 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2023-10-19 / Methods Cell Biol 2024;183:51-1132023-10-19 00:00:002024-04-20 10:47:17Methods behind oncolytic virus-based DC vaccines in cancer: Toward a multiphase combined treatment strategy for Glioblastoma (GBM) patients

Dendritic cell vaccination for glioblastoma multiforme patients: has a new milestone been reached?

2023-07-28
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2023-07-28 / Transl Cancer Res 2023 Aug;12(8):2224-2228 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2023-07-28 / Transl Cancer Res 2023 Aug;12(8):2224-22282023-07-28 00:00:002024-04-17 15:08:24Dendritic cell vaccination for glioblastoma multiforme patients: has a new milestone been reached?

The Application of Evidence-Based Medicine in Individualized Medicine

2023-06-23
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2023-06-23 / Biomedicines 2023 Jun;11(7) https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2023-06-23 / Biomedicines 2023 Jun;11(7)2023-06-23 00:00:002024-04-17 15:04:06The Application of Evidence-Based Medicine in Individualized Medicine

Individualized Multimodal Immunotherapy for Adults with IDH1 Wild-Type GBM: A Single Institute Experience

2023-02-13
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2023-02-13 / Cancers (Basel) 2023 Feb;15(4) https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2023-02-13 / Cancers (Basel) 2023 Feb;15(4)2023-02-13 00:00:002023-05-30 16:20:40Individualized Multimodal Immunotherapy for Adults with IDH1 Wild-Type GBM: A Single Institute Experience

Poster presentation at the annual meeting of the Association for Cancer Immunotherapy

2022-06-02
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2022-02-28 / Biomedicines 2022 Feb;10(3) https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2022-02-28 / Biomedicines 2022 Feb;10(3)2022-06-02 00:00:002025-03-27 05:35:20Posterpräsentation auf der Jahrestagung der Association for Cancer Immunotherapy

Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients

2022-02-16
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2022-02-16 / Genes Immun 2022 Feb; https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2022-02-16 / Genes Immun 2022 Feb;2022-02-16 00:00:002022-02-21 07:49:56Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients

Stem cells-derived natural killer cells for cancer immunotherapy: current protocols, feasibility, and benefits of ex vivo generated natural killer cells in treatment of advanced solid tumors

2021-07-04
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2021-07-04 / Cancer Immunol Immunother 2021 Jul; https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2021-07-04 / Cancer Immunol Immunother 2021 Jul;2021-07-04 00:00:002021-11-15 12:29:15Stem cells-derived natural killer cells for cancer immunotherapy: current protocols, feasibility, and benefits of ex vivo generated natural killer cells in treatment of advanced solid tumors

Randomized Controlled Immunotherapy Clinical Trials for GBM Challenged

2020-12-24
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2020-12-24 / Cancers (Basel) 2020 Dec;13(1) https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2020-12-24 / Cancers (Basel) 2020 Dec;13(1)2020-12-24 00:00:002021-11-15 13:17:14Randomized Controlled Immunotherapy Clinical Trials for GBM Challenged

Evidence-Based Medicine in Oncology: Commercial Versus Patient Benefit

2020-07-23
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2020-07-23 / Biomedicines 2020 Jul;8(8) https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2020-07-23 / Biomedicines 2020 Jul;8(8)2020-07-23 00:00:002021-11-15 19:51:32Evidence-Based Medicine in Oncology: Commercial Versus Patient Benefit

Position paper: new insights into the immunobiology and dynamics of tumor-host interactions require adaptations of clinical studies

2020-06-30
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2020-06-30 / Expert Rev Anticancer Ther 2020 Aug;20(8):639-646 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2020-06-30 / Expert Rev Anticancer Ther 2020 Aug;20(8):639-6462020-06-30 00:00:002021-11-15 13:19:48Position paper: new insights into the immunobiology and dynamics of tumor-host interactions require adaptations of clinical studies

Addition of Multimodal Immunotherapy to Combination Treatment Strategies for Children with DIPG: A Single Institution Experience

2020-05-19
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2020-05-19 / Medicines (Basel) 2020 May;7(5) https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2020-05-19 / Medicines (Basel) 2020 May;7(5)2020-05-19 00:00:002021-11-15 20:10:42Addition of Multimodal Immunotherapy to Combination Treatment Strategies for Children with DIPG: A Single Institution Experience

Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy

2019-08-30
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2019-08-30 / Biomedicines 2019 Aug;7(3) https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2019-08-30 / Biomedicines 2019 Aug;7(3)2019-08-30 00:00:002021-11-15 13:22:59Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy

Long-term survival of a breast cancer patient with extensive liver metastases upon immune and virotherapy: a case report

2015-05-28
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2015-05-28 / Immunotherapy 2015;7(8):855-60 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2015-05-28 / Immunotherapy 2015;7(8):855-602015-05-28 00:00:002021-11-16 07:55:05Long-term survival of a breast cancer patient with extensive liver metastases upon immune and virotherapy: a case report

Long-term remission of prostate cancer with extensive bone metastases upon immuno- and virotherapy: A case report

2014-10-06
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2014-10-06 / Oncol Lett 2014 Dec;8(6):2403-2406 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2014-10-06 / Oncol Lett 2014 Dec;8(6):2403-24062014-10-06 00:00:002021-11-16 07:53:33Long-term remission of prostate cancer with extensive bone metastases upon immuno- and virotherapy: A case report

Further information on this topic:

  • Team
  • IOZK Immunotherapy
  • IOZK Foundation

The IOZK

  • Philosophy
  • Team
  • Treatment center
  • Laboratories
  • Career
  • Arrival and overnight stay

Worth knowing

  • Evidence-based medicine at the IOZK
  • Laboratories at the IOZK
  • Magazine of the IOZK Foundation: IOZK Consilium
  • Video: Patient Mrs. Ebel about her experiences with IOZK immunotherapy
  • Video: Patient reports on experiences with IOZK immunotherapy
  • Information brochure of the IOZK Foundation
  • Personalized medicine in oncology
  • The development of cancer
  • What does immunotherapy mean?
  • Nobel Prizes for immunotherapy

Experts in Tumor Immunology

  • TikTok
  • Instagram
  • LinkedIn
  • YouTube
  • Podcast
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland

T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de

The IOZK

  • Philosophy
  • Team
  • Treatment center
  • Laboratories
  • Career
  • Arrival and overnight stay

The IOZK immunotherapy

  • IOZK immunotherapy
  • The IO-VAC® vaccine
  • Treatment procedure
  • Therapy costs
  • FAQ

IOZK Publications

  • The Complexity of Malignant Glioma Treatment
  • Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution
  • Neue IOZK Veröffentlichung zum Thema Liquid Biopsy
© 2025 IOZK Immun-Onkologisches Zentrum Köln
  • Imprint
  • Privacy policy
  • Cookie settings
  • Press
Nach oben scrollen